Close
Achema middle east
swop processing & packaging

FDA approves Sunovion Latuda label update to extend dose range

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Optimizing Pharma Packaging for Shipping & Distribution Resilience

Building Robust Supply Chain Networks Through Strategic Packaging Design The...

Pharma Packaging Traceability: Drug to Patient Compliance Tool

Traceability from Drug to Patient: Packaging as a Compliance...

End-of-Line Pharma Packaging Trends in Automated Palletizing

End-of-Line Pharma Packaging: Trends in Automated Palletizing & Depalletizing Transforming...

The FDA has approved the stretched dose range for Sunovion Pharmaceuticals’ Latuda for the treatment of patients with schizophrenia.

After the review of the supplemental new drug application (sNDA), which was submitted in June 2011, the FDA has announced the decision.

Sunovion executive vice president and chief medical officer Antony Loebel said, “Schizophrenia is a complex disorder that requires a careful assessment of each patient. Having added dosing flexibility for LATUDA will allow physicians to better tailor treatment to the individual needs of patients with schizophrenia.”

The newly extended recommended dose range for Latuda (40-160mg/day) consists of approval of the 120mg/day and 160mg/day doses, as well as a new 120mg tablet, the company said.

The expanded dose range reflects positive results from five short-term studies that evaluated the safety and efficacy of Latuda where doses were shown to be safe and effective.

Latest stories

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Optimizing Pharma Packaging for Shipping & Distribution Resilience

Building Robust Supply Chain Networks Through Strategic Packaging Design The...

Pharma Packaging Traceability: Drug to Patient Compliance Tool

Traceability from Drug to Patient: Packaging as a Compliance...

End-of-Line Pharma Packaging Trends in Automated Palletizing

End-of-Line Pharma Packaging: Trends in Automated Palletizing & Depalletizing Transforming...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »